Seo Ree Kim

Seo Ree Kim

Auto-generated profile, based on publicly available information

Seo Ree Kim

Division of Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
SKSeoree Kim
Seoree Kim
KSKabsoo Shin
Kabsoo Shin
JPJae Myung Park
Jae Myung Park
HLHan Hong Lee
Han Hong Lee
KSKyo Yong Song
Kyo Yong Song
IKIn-Ho Kim
In-Ho Kim
Kim SR, et al. J Gastric Cancer. 2020 Dec;20(4):408-420. https://doi.org/10.5230/jgc.2020.20.e33

18 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
DKDaeseung Kim
Daeseung Kim
JKJeong Seon Kim
Jeong Seon Kim
ICInyoung Cheon
Inyoung Cheon
SKSeoree Kim
Seoree Kim
SCSang Hoon Chun
Sang Hoon Chun
YKYoon Ho Ko
Yoon Ho Ko
Cancer-associated fibroblasts (CAFs) reside within the tumor microenvironment, facilitating cancer progression and metastasis via direct and indirect interactions with cancer cells and other stromal cell types. CAFs are composed of heterogeneous subpopulations of activated fibroblasts, including myofibroblastic, inflammatory, and immunosuppressive CAFs. In this study, we sought to identify subpopulations of CAFs isolated from human lung adenocarcinomas and describe their transcriptomic and functional characteristics through single-cell RNA sequencing (scRNA-seq) and subsequent bioinformatics analyses. Cell trajectory analysis of combined total and THY1 + CAFs revealed two branching points with five distinct branches. Based on Gene Ontology analysis, we denoted Branch 1 as “immunosuppressive”, Branch 2 as “neoantigen presenting”, Branch 4 as “myofibroblastic”, and Branch 5 as “proliferative” CAFs. We selected representative branch-specific markers and measured their expression levels in total and THY1 + CAFs. We also investigated the effects of these markers on CAF activity under coculture with lung cancer cells. This study describes novel subpopulations of CAFs in lung adenocarcinoma, highlighting their potential value as therapeutic targets.

1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JCJae-Ki Choi
Jae-Ki Choi
SKSunghan Kim
Sunghan Kim
SKSeoree Kim
Seoree Kim
JJJong-Youl Jin
Jong-Youl Jin
SCSeon Woong Choi
Seon Woong Choi
SKSeong-Rim Kim
Seong-Rim Kim
Choi JK, et al. J Korean Med Sci. 2021 Aug;36(31):e223. https://doi.org/10.3346/jkms.2021.36.e223

26 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
JKJeong-Oh Kim
Jeong-Oh Kim
JSJung-Young Shin
Jung-Young Shin
SKSeoree Kim
Seoree Kim
KSKab Soo Shin
Kab Soo Shin
JKJoori Kim
Joori Kim
JKJin Hyoung Kang
Jin Hyoung Kang
Epidermal growth factor receptor (EGFR) mutation testing is essential for individualized treatment using tyrosine kinase inhibitors. We evaluated two EGFR mutation tests, cobas v2 and PANAMutyper, for detection of EGFR activating mutations Ex19del, L858R, and T790M in tumor tissue and plasma from 244 non-small cell lung cancer (NSCLC) patients. The Kappa coefficient (95% CI) between the tests was 0.82 (0.74–0.92) in tumor samples (suggesting almost perfect agreement) and 0.69 (0.54–0.84) in plasma (suggesting substantial agreement). In plasma samples, both tests showed low to moderate sensitivity depending on disease stage but high diagnostic precision (86%–100%) in all disease stages (sensitivity: percentage of mutations in tumors that are also detected in plasma; precision: percentage of mutations in plasma which are also detected in tumors). Among the 244 patients, those previously diagnosed as T790M carriers who received osimertinib treatment showed dramatically better clinical outcomes than T790M carriers without osimertinib treatment. Taken together, our study supports interchangeable use of cobas v2 and PANAMutyper in tumor and plasma EGFR testing. Both tests have high diagnostic precision in plasma but are particularly valuable in late-stage disease. Our clinical data in T790M carriers strongly support the clinical benefits of osimertinib treatment guided by both EGFR mutation tests.

8 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HLHeejin Lee
Heejin Lee
SCSang Hoon Chun
Sang Hoon Chun
SMSeo Yun Moon
Seo Yun Moon
JYJung-Sook Yoon
Jung-Sook Yoon
HWHye Sung Won
Hye Sung Won
YKYoon Ho Ko
Yoon Ho Ko
MiR-769-3p expression is suppressed in the stromal subtype of head and neck squamous cell carcinoma (HNSCC); however, its role in stromal HNSCC has not been fully elucidated. To investigate the biological relevance of miR-769-3p in the stromal phenotype, we established oral squamous cell cancer (OSCC) cell lines, namely CAL27, HSC3, and YD8, overexpressing miR-769-3p. miR-769-3p expression was positively and negatively correlated with interferon-gamma-related genes and MYC target gene sets, respectively. miR-769-3p decreased OSCC cell migration and invasion as well as mesenchymal marker expression and increased epithelial marker expression. Moreover, miR-769-3p enhanced OSCC cell sensitivity to 5-fluorouracil. High miR-769-3p expression was associated with good prognosis of HNSCC patients. Collectively, these results suggest that miR-769-3p suppression enhances stromal gene expression and promotes the epithelial-to-mesenchymal transition. Therefore, miR-769-3p may be a potential biomarker of the miRNA phenotype in OSCC patients.

9 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
TKTong Yoon Kim
Tong Yoon Kim
Tae-Jung KimTae-Jung Kim
Tae-Jung Kim
EHEun Ji Han
Eun Ji Han
GMGi June MIN
Gi June MIN
SCSeok-Goo Cho
Seok-Goo Cho
YJYoungwoo Jeon
Youngwoo Jeon
Background/Objectives: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are low-grade B-cell lymphomas (LGBCLs) with indolent clinical courses but a lifelong risk of histologic transformation (HT) to aggressive lymphomas, particularly diffuse large B-cell lymphoma. Predicting HT can be challenging due to class imbalances and the inherent complexity of time-dependent events. While there are current prognostic indices for survival, they do not specifically address HT risk. This study aimed to develop and validate survival-based and traditional classification machine-learning models to predict HT in cohorts. Methods: Using a multicenter retrospective dataset (n = 1068), survival models (Cox proportional hazards, Lasso-Cox, Random Survival Forest, Gradient-boosted Cox [GBM-Cox], eXtreme Gradient Boosting [XGBoost]-Cox), and classification models (Logistic regression, Lasso logistic, Random Forest, Gradient Boosting, XGBoost) were compared. The best-performing survival models—XGBoost-Cox, Lasso-Cox, and GBM-Cox—were assessed on an independent test set (n = 92). Model sensitivity was maximized using optimal binary risk cutoff points based on Youden’s index. Results: Survival models showed superior predictive performance than classical classifiers, with XGBoost-Cox exhibiting the highest mean accuracy (85.3%), time-dependent area under the curve (0.795), sensitivity (98%), specificity (83.9%), and concordance index (0.836). Incorporating next-generation sequencing (NGS) data improved model accuracy and specificity, indicating that genetic factors improve HT prediction. Principal component analysis revealed distinct gene mutation patterns associated with HT risk, highlighting DNA-repair genes such as TP53, BLM, and RAD50. Conclusions: This study highlights the clinical value of survival-based machine-learning methods integrated with NGS data to personalize HT risk stratification for patients with FL and MZL.